Watchful waiting or watchful progression?

Duncan B. McLaren(NHS Lothian), Tom Pickles, Michael McKenzie(Provincial Health Services Authority), Graeme Duncan(BC Cancer Agency)

Cancer

January 15, 1998

10.1002/(sici)1097-0142(19980115)82:2<349::aid-cncr15>3.0.co;2-z

Cited by 98

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

|The Lancet|2015|2k

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

|International Journal of Radiation Oncology*Biology*Physics|2016|736

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

|The Lancet Oncology|2019|649

Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy

|International Journal of Radiation Oncology*Biology*Physics|2008|532

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer

|International Journal of Radiation Oncology*Biology*Physics|2017|319